These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9871586)

  • 21. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and human immunodeficiency virus (HIV)-1 protease inhibitory activity of tripeptide analogues containing a dioxoethylene moiety.
    Kitazaki T; Asano T; Kato K; Kishimoto S; Itoh K
    Chem Pharm Bull (Tokyo); 1994 Dec; 42(12):2636-40. PubMed ID: 7697778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A
    Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
    Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
    J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 protease inhibitors: ketomethylene isosteres with unusually high affinity compared with hydroxyethylene isostere analogs.
    Marinier A; Toth MV; Houseman K; Mueller R; Marshall GR
    Bioorg Med Chem; 1994 Sep; 2(9):919-25. PubMed ID: 7712127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NMR and topochemical studies of peptidomimetic HIV-I protease inhibitors containing a cis-epoxide amide isostere.
    Ro S; Baek SG; Lee B; Park C; Choy N; Lee CS; Son YC; Choi H; Koh JS; Yoon H; Kim SC; Ok JH
    Bioorg Med Chem Lett; 1998 Sep; 8(18):2423-6. PubMed ID: 9873554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
    Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
    Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
    Mak CC; Le VD; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem Lett; 2001 Jan; 11(2):219-22. PubMed ID: 11206463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs.
    Hong L; Zhang XJ; Foundling S; Hartsuck JA; Tang J
    FEBS Lett; 1997 Dec; 420(1):11-6. PubMed ID: 9450540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The inhibition of HIV-1 protease by interface peptides.
    Schramm HJ; Billich A; Jaeger E; Rücknagel KP; Arnold G; Schramm W
    Biochem Biophys Res Commun; 1993 Jul; 194(2):595-600. PubMed ID: 8343146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
    Lu Z; Raghavan S; Bohn J; Charest M; Stahlhut MW; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2003 May; 13(10):1821-4. PubMed ID: 12729673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases.
    Tözsér J; Weber IT; Gustchina A; Bláha I; Copeland TD; Louis JM; Oroszlan S
    Biochemistry; 1992 May; 31(20):4793-800. PubMed ID: 1591240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.
    Newlander KA; Callahan JF; Moore ML; Tomaszek TA; Huffman WF
    J Med Chem; 1993 Aug; 36(16):2321-31. PubMed ID: 8360876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
    Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
    Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J; Wallberg H; Vrang L; Oscarson S; Parkes K; Hallberg A; Samuelsson B
    Eur J Med Chem; 2010 Jan; 45(1):160-70. PubMed ID: 19926360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.